# Title

 Food and Drugs. PART 864â€”HEMATOLOGY AND PATHOLOGY DEVICES


# ID

 CFR-2018-title21-vol8.Pt. 864


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'more than', 'prior to', 'after', 'minimum of', 'minimum', 'at least']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Duration    | ['2.0 week']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Condition   | ['if', 'where', 'subject to', 'when', 'unless']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Entities    | ['Empty', 'Carboxyhemoglobin', 'Balanced', 'Red', 'Similar', 'Copper', 'Sulfhemoglobin', 'Hematocrit', 'Platelet', 'Fibrin', 'Early', 'Blood', 'Heparin', 'Occult', 'Immunohistochemistry', 'Automated', 'Adenosine', 'Color', 'Synthetic', 'Erythropoietin', 'Leukocyte', 'Prothrombin', 'Flow', 'Coombs', 'Dye', 'Whole', 'Partial', 'Documentation', 'Bothrops', 'Transfer', 'Tissue', 'Cultured', 'Chromosome', 'Animal', 'Electrophoretic', 'Vitro', 'Scope', 'Thermus', 'Fibrinogen', 'Environmental', 'Euglobulin', 'Specimen', 'Food', 'Cervical', 'Multipurpose', 'Thrombin', 'Calibrator', 'Lymphocyte', 'Enzyme', 'Cytocentrifuge', 'Industry and FDA', 'Quick', 'Mycoplasma', 'Glutathione', 'Abnormal', 'Factor', 'Osmotic', 'Microsedimentation', 'Device', 'Manual', 'Turnaround', 'Papanicolaou', 'Cell', 'Sickle', 'Cord', 'Guidance', 'Lynch', 'Coagulation', 'Fetal', 'Elevated', 'Thromboplastin', 'Analyte', 'Hematology', 'Erythrocyte'] |
| Date        | ['2018-09-01', '2018-12-01', '1998-11-23', '2018-02-03', '1976-05-28']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                                |
|:--------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------|
| after         | III (premarket approval) shall not be commercially distributed after the date shown in the regulation classifying the                                  |
| before        | Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a                                           |
| before        | Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a                                           |
| after         | the grace period ending on the 90th day after its promulgation or on the last day of                                                                   |
| after         | the grace period ending on the 90th day after its promulgation or on the last day of                                                                   |
| after         | equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed                              |
| before        | or declaring completed a PDP for the device before the device is commercially distributed unless it is                                                 |
| before        | an approval under section 515 of the act before  commercial distribution.                                                                              |
| within        | or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of                              |
| before        | must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce                           |
| after         | These IHC's are used  after the primary diagnosis of tumor (neoplasm) has been                                                                         |
| before        | device described in paragraph (b)(3) of this section before  this device may be commercially distributed.                                              |
| minimum of    | (e.g., for distributed tests, data generated using a minimum of three sites, of which at least two sites                                               |
| at least      | using a minimum of three sites, of which at least  two sites must be external sites).                                                                  |
| minimum of    | Each site must perform testing over a  minimum of 5 nonconsecutive days evaluating a sample panel that                                                 |
| minimum of    | documentation must include data from clinical studies, a minimum of two peer-reviewed published literature references using the specific               |
| minimum       | culture tissues for diagnosis of congenital chromosome abnormalities. minimum                                                                          |
| more than     | reagents are appropriate for combining with one or more than one ASR in producing such systems and include                                             |
| more than     | Reagents used in tests for  more than one individual chemical substance or ligand are general                                                          |
| within        | ASR's that otherwise fall  within  this definition are not                                                                                             |
| within        | ASR's that otherwise fall  within  this definition are not                                                                                             |
| minimum of    | between run, site-to-site and total variation using a minimum of three sites, of which at least two sites                                              |
| at least      | using a minimum of three sites, of which at least  two sites must be external sites.                                                                   |
| minimum of    | (D) Reproducibility data generated using a  minimum of three lots of reagents to evaluate mean fluorescence                                            |
| after         | evaluates natural fibrinolysis (destruction of a blood clot after  bleeding has been arrested).                                                        |
| within        | the diagnosis of disseminated intravascular coagulation (nonlocalized clotting within a blood vessel) or in the differential diagnosis                 |
| within        | fibrinogen levels in disseminated intravascular coagulation (nonlocalized clotting within the blood vessels) and primary fibrinolysis (the dissolution |
| prior to      | a device used to glycerolize red blood cells prior to freezing to minimize hemolysis (disruption of the red                                            |
| prior to      | or plasma, by means other than electromagnetic radiation, prior to  administration.                                                                    |
| prior to      | a bag or bottle of blood or plasma prior to  administration.                                                                                           |
| within        | is a device used to hold platelet-rich plasma within  a preselected temperature range.                                                                 |


## Duration

| Duration   | Context                                                                                                                                                                                                                   |
|:-----------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.0 week   | (C) Data demonstrating reader reproducibility, both within-reader and between-reader, assessed by three readers over 3 nonconsecutive days at each site, including a 2 week washout period between reads, as appropriate. |


## Condition

| Condition   | Context                                                                                                                 |
|:------------|:------------------------------------------------------------------------------------------------------------------------|
| subject to  | of every device that is, or will be, subject to  the regulation.                                                        |
| unless      | Regulations are to chapter I of title 21, unless  otherwise noted.                                                      |
| unless      | date shown in the regulation classifying the device unless the manufacturer has an approval under section 515           |
| unless      | Accordingly,  unless an effective date of the requirement for premarket                                                 |
| unless      | the device before the device is commercially distributed unless  it is reclassified.                                    |
| where       | or the device is intended for lay use where the former intended use was by health care                                  |
| when        | other than immunoglobulin G (IgG) or IgG assays when the results are not qualitative, or are used                       |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| if          | software applications and hardware-based devices that incorporate software. if                                          |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | in part 807, subpart E of this chapter subject to the limitations in &#167;&#8201;864.9 if it is sold,                  |
| if          | The device is exempt from the premarket not if ication requirements in part 807, subpart E of                           |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| when        | manual digital (MD) and manual optical (MO) modalities when  compared to the reference (e.g., main sign-out diagnosis). |
| if          | (iv) A limiting statement that spec if ies that pathologists should exercise professional judgment in                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| when        | an individual substance, or multiple substances reformulated, which, when combined with or used in conjunction with an  |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| when        | the scope of subpart E of this part when they are sold to: (1) In vitro diagnostic                                      |
| when        | (2) Class II (special controls/guidance documents),  when the analyte is used in blood banking tests                    |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| if          | The description must ident if y those control elements that are incorporated into                                       |
| if          | of the results, a description of the spec if ic number of events to collect, result outputs,                            |
| if          | specimens including all hematologic neoplasms and the spec if ic sample types for which the device is                   |
| when        | reference to demonstrate that no additional population appears when  one marker is absent.                              |
| when        | used to determine the carboxyhemoglobin (the compound formed when hemoglobin is exposed to carbon monoxide) content of  |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;864.9.                                |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |
| subject to  | subpart E of part 807 of this chapter subject to  &#167;&#8201;864.9.                                                   |


## Entities

| Entities             | Context                                                                                                                                                |
|:---------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                 | Food  and Drugs.                                                                                                                                       |
| Scope                | Scope .                                                                                                                                                |
| Dye                  | Dye  and chemical solution stains.                                                                                                                     |
| Dye                  | Dye and chemical solution stains for medical purposes are                                                                                              |
| Immunohistochemistry | Immunohistochemistry  reagents and kits.                                                                                                               |
| Immunohistochemistry | Immunohistochemistry test systems (IHC's) are in vitro diagnostic devices                                                                              |
| Similar              | Similar devices intended for use with flow cytometry devices                                                                                           |
| Cervical             | Cervical  intraepithelial neoplasia (CIN) test system.                                                                                                 |
| Papanicolaou         | limited to, prior and current cervical biopsy results, Papanicolaou (Pap) test results, human papillomavirus (HPV) test results,                       |
| Lynch                | Lynch  syndrome test systems.                                                                                                                          |
| Lynch                | Lynch syndrome test systems are in vitro diagnostic tests                                                                                              |
| Lynch                | Lynch syndrome test systems are in vitro diagnostic tests                                                                                              |
| Lynch                | to Deoxyribonucleic Acid (DNA) sequencing results of the Lynch syndrome associated genes or method comparison to the                                   |
| Lynch                | to Deoxyribonucleic Acid (DNA) sequencing results of the Lynch syndrome associated genes or method comparison to the                                   |
| Early                | Early growth response 1 (EGR1) gene fluorescence in-situ hybridization                                                                                 |
| Documentation        | Documentation for the clinical studies and peer-reviewed published literature                                                                          |
| Synthetic            | Synthetic cell and tissue culture media and components are                                                                                             |
| Cell                 | Cell  and tissue culture supplies and equipment.                                                                                                       |
| Cell                 | Cell and tissue culture supplies and equipment are devices                                                                                             |
| Chromosome           | Chromosome  culture kit.                                                                                                                               |
| Cultured             | Cultured  animal and human cells.                                                                                                                      |
| Cultured             | Cultured animal and human cells are in vitro cultivated                                                                                                |
| Mycoplasma           | Mycoplasma  detection media and components.                                                                                                            |
| Mycoplasma           | Mycoplasma detection media and components are used to detect                                                                                           |
| Animal               | Animal  and human sera.                                                                                                                                |
| Animal               | Animal and human sera are biological products, obtained from                                                                                           |
| Balanced             | Balanced  salt solutions or formulations.                                                                                                              |
| Tissue               | Tissue  processing equipment.                                                                                                                          |
| Tissue               | Tissue processing equipment consists of devices used to prepare                                                                                        |
| Specimen             | Specimen  transport and storage container.                                                                                                             |
| Cytocentrifuge       | Cytocentrifuge .                                                                                                                                       |
| Device               | Device  for sealing microsections.                                                                                                                     |
| Whole                | Whole  slide imaging system.                                                                                                                           |
| Color                | level, including for the following, as appropriate: (A) Color reproducibility; (B) Spatial resolution; (C) Focusing test; (D)                          |
| Turnaround           | slide tissue coverage; (E) Stitching error; and (F) Turnaround  time.                                                                                  |
| Automated            | Automated  slide stainer.                                                                                                                              |
| Thermus              | substance or ligand are general purpose reagents (e.g., Thermus  aquaticus (TAQ) polymerase, substrates for enzyme immunoassay (EIA)).                 |
| Analyte              | Analyte  specific reagents.                                                                                                                            |
| Analyte              | Analyte specific reagents (ASR's) are antibodies, both polyclonal and                                                                                  |
| Guidance             | Guidance  Documents:                                                                                                                                   |
| Enzyme               | Enzyme  preparations.                                                                                                                                  |
| Enzyme               | Enzyme preparations are products that are used in the                                                                                                  |
| Industry and FDA     | Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA .&#8221;                                                                         |
|                      |               Automated blood cell diluting apparatus.                                                                                                 |
| Red                  | Red  cell indices device.                                                                                                                              |
| Microsedimentation   | Microsedimentation  centrifuge.                                                                                                                        |
| Coagulation          | Coagulation  instrument.                                                                                                                               |
| Multipurpose         | Multipurpose  system for in vitro coagulation studies.                                                                                                 |
| Automated            | Automated  hemoglobin system.                                                                                                                          |
| Automated            | Automated  heparin analyzer.                                                                                                                           |
| Automated            | Automated  slide spinner.                                                                                                                              |
| Blood                | Blood  volume measuring device.                                                                                                                        |
| Manual               | Manual  blood cell counting device.                                                                                                                    |
| Hematocrit           | Hematocrit  measuring device.                                                                                                                          |
| Abnormal             | Abnormal states include anemia (an abnormally low total red                                                                                            |
| Occult               | Occult  blood test.                                                                                                                                    |
| Osmotic              | Osmotic  fragility test.                                                                                                                               |
| Platelet             | Platelet  adhesion test.                                                                                                                               |
| Platelet             | Platelet  aggregometer.                                                                                                                                |
| Erythrocyte          | Erythrocyte  sedimentation rate test.                                                                                                                  |
| Flow                 | Flow  cytometric test system for hematopoietic neoplasms.                                                                                              |
| Adenosine            | Adenosine  triphosphate release assay.                                                                                                                 |
| Erythropoietin       | Erythropoietin  assay.                                                                                                                                 |
| Euglobulin           | Special Controls for Erythropoietin Assay Premarket Notification (510(k)s).&#8221; Euglobulin  lysis time tests.                                       |
| Factor               | Factor  deficiency test.                                                                                                                               |
| Fibrin               | Fibrin  monomer paracoagulation test.                                                                                                                  |
| Vitro                | special control for this device is FDA's &#8220;In Vitro Diagnostic Fibrin Monomer Paracoagulation Test.&#8221; Fibrinogen/fibrin degradation products |
| Fibrinogen           | Fibrinogen  determination system.                                                                                                                      |
| Glutathione          | Glutathione  reductase assay.                                                                                                                          |
| Abnormal             | Abnormal  hemoglobin assay.                                                                                                                            |
| Carboxyhemoglobin    | Carboxyhemoglobin  assay.                                                                                                                              |
| Electrophoretic      | Electrophoretic  hemoglobin analysis system.                                                                                                           |
| Fetal                | Fetal  hemoglobin assay.                                                                                                                               |
| Elevated             | Elevated levels of glycosylated hemoglobin indicate uncontrolled diabetes in                                                                           |
| Sulfhemoglobin       | Sulfhemoglobin  assay.                                                                                                                                 |
| Whole                | Whole  blood hemoglobin assays.                                                                                                                        |
| Heparin              | Heparin  assay.                                                                                                                                        |
| Leukocyte            | Leukocyte  alkaline phosphatase test.                                                                                                                  |
| Leukocyte            | Leukocyte  peroxidase test.                                                                                                                            |
| Platelet             | Platelet  factor 4 radioimmunoassay.                                                                                                                   |
| Prothrombin          | Prothrombin  consumption test.                                                                                                                         |
| Quick                | in conjunction with, or in place of, the Quick  prothrombin time test to detect coagulation disorders.                                                 |
| Prothrombin          | Prothrombin  time test.                                                                                                                                |
| Sickle               | Sickle  cell test.                                                                                                                                     |
| Thrombin             | Thrombin  time test.                                                                                                                                   |
| Thromboplastin       | Thromboplastin  generation test.                                                                                                                       |
| Partial              | Partial  thromboplastin time tests.                                                                                                                    |
| Bothrops             | Bothrops  atrox reagent.                                                                                                                               |
| Calibrator           | Calibrator  for cell indices.                                                                                                                          |
| Calibrator           | Calibrator  for hemoglobin or hematocrit measurement.                                                                                                  |
| Calibrator           | Calibrator  for platelet counting.                                                                                                                     |
| Calibrator           | Calibrator  for red cell and white cell counting.                                                                                                      |
| Blood                | Blood  cell diluent.                                                                                                                                   |
| Lymphocyte           | Lymphocyte  separation medium.                                                                                                                         |
| Red                  | Red  cell lysing reagent.                                                                                                                              |
| Hematology           | Hematology  quality control mixture.                                                                                                                   |
| Blood                | Blood  bank supplies.                                                                                                                                  |
| Blood                | Blood bank supplies are general purpose devices intended for                                                                                           |
| Empty                | Empty container for the collection and processing of blood                                                                                             |
| Blood                | Blood group substances of nonhuman origin for in vitro                                                                                                 |
| Blood                | Blood group substances of nonhuman origin for in vitro                                                                                                 |
| Blood                | Blood  grouping view box.                                                                                                                              |
| Blood                | Blood  mixing devices and blood weighing devices.                                                                                                      |
| Blood                | Blood  and plasma warming device.                                                                                                                      |
| Blood                | entitled &#8220;Class II Special Controls Guidance Document: Automated Blood Cell Separator Device Operating by Centrifugal or Filtration              |
| Coombs               | The  Coombs test is used for the diagnosis of hemolytic                                                                                                |
| Copper               | Copper  sulfate solution for specific gravity determinations.                                                                                          |
| Environmental        | Environmental  chamber for storage of platelet concentrate.                                                                                            |
| Blood                | Blood  storage refrigerator and blood storage freezer.                                                                                                 |
| Transfer             | Transfer  set.                                                                                                                                         |
| Cord                 | Cord  blood processing system and storage container.                                                                                                   |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1976-05-28 | (b) Any new, not substantially equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed that has been substantially altered, is classified by statute (section 513(f) of the act) into class III without any grace period and FDA must have issued an order approving a PMA or declaring completed a PDP for the device before the device is commercially distributed unless it is reclassified. |
| 1976-05-28 | Accordingly, the regulation for such a class III device states that as of the enactment date of the amendments, May 28, 1976, the device must have an approval under section 515 of the act before commercial distribution.                                                                                                                                                                                                                                       |
| 1976-05-28 | As of May 28, 1976, an approval under section 515 of the Federal Food, Drug, and Cosmetic Act is required for any device described in paragraph (b)(3) of this section before this device may be commercially distributed.                                                                                                                                                                                                                                        |
| 1998-11-23 | (2) For postamendments ASR's; November 23, 1998.                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 2018-02-03 | Red blood cell enzyme assay is a device used to measure the activity in red blood cells of clinically important enzymatic reactions and their products, such as pyruvate kinase or 2,3-diphosphoglycerate.                                                                                                                                                                                                                                                        |
| 2018-12-01 | The measurement of hemoglobin A2 is used in the diagnosis of the thalassemias (hereditary hemolytic anemias characterized by decreased synthesis of one or more types of hemoglobin polypeptide chains).                                                                                                                                                                                                                                                          |
| 2018-09-01 | A blood bank centrifuge for in vitro diagnostic use is a device used only to separate blood cells for further diagnostic testing.                                                                                                                                                                                                                                                                                                                                 |


